Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91

To analyse long-term outcome and clinical prognostic factors in medulloblastoma. We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chem...

Full description

Saved in:
Bibliographic Details
Published in:European Journal of Cancer 2009-05, Vol.45 (7), p.1209-1217
Main Authors: VON HOFF, Katja, HINKES, Bernward, GOETTE, Heiko, SCHLEGEL, Paul G, PIETSCH, Torsten, KORTMANN, Rolf D, KUEHL, Joachim, RUTKOWSKI, Stefan, GERBER, Nicolas U, DEINLEIN, Frank, MITTLER, Uwe, URBAN, Christian, BENESCH, Martin, WARMUTH-METZ, Monika, SOERENSEN, Niels, ZWIENER, Isabella
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cerebellar Neoplasms - drug therapy
Cerebellar Neoplasms - radiotherapy
Cerebellar Neoplasms - surgery
Child
Child, Preschool
Combined Modality Therapy
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Male
Medical sciences
Medulloblastoma - drug therapy
Medulloblastoma - radiotherapy
Medulloblastoma - surgery
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm, Residual
Neoplasms, Second Primary
Pharmacology. Drug treatments
Proportional Hazards Models
Survival Rate
Treatment Outcome
Tumors
Vincristine - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To analyse long-term outcome and clinical prognostic factors in medulloblastoma. We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years). In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independent adverse risk factors. Twelve percent of all relapses (13 of 107) occurred after more than five years, and 12 patients had secondary neoplasms. After maintenance therapy, long-term survival was excellent in fully assessable patients with localised medulloblastoma, and favourable for M1 patients. Patients should be followed longer for late relapses and secondary tumours.
ISSN:0959-8049
1879-0852
1359-6349
DOI:10.1016/j.ejca.2009.01.015